CERO THERAPEUTICS HOLDINGS I (CERO) Stock Income Statement
NASDAQ:CERO - US71902K4022 - Common Stock
7.67 USD
-0.23 (-2.91%)
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 16.60M | 16.20M | 2.93M | 2.91M | 332.00K | |||
| Research and Development | 8.32M | 7.08M | N/A | N/A | N/A | |||
| Selling, General, and Administrative Expenses | 8.28M | 9.12M | 2.93M | 2.91M | 332.00K | |||
| Operating Income | -16.60M | -16.20M | -2.93M | -2.91M | -332.00K | |||
| Interest Income/Expense | 3.12M | 5.23M | 491.60K | 2.84M | -400.00 | |||
| Other Income/Expense | 2.37M | 2.67M | N/A | N/A | N/A | |||
| Income Before Taxes | -11.11M | -8.30M | -2.44M | -68.60K | -332.40K | |||
| Income Tax | N/A | N/A | 94.80K | 599.20K | -16.90K | |||
| Net Income | -14.24M | -11.09M | -2.54M | -667.70K | -315.50K | |||
| EBITDA | -16.20M | -15.76M | N/A | N/A | N/A | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -377.43 | -382.78 | -340.42 | -89.62 | -0.01 | |||
| Statistics | ||||||||
All data in USD